| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | Large T antigen; LT; LT-AG |
| Entrez GeneID | 29031019 |
| WB Predicted band size | Calculated MW: 82 kDa; Observed MW: 90 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | All |
| Immunogen | A synthetic peptide of SV40 T-antigen |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于GALNT12抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Germline mutations in the polyposis-associated gene GALNT12*
**作者**: Juan R. Reis, et al.
**摘要**: 该研究首次发现GALNT12基因的种系突变与家族性结直肠癌相关。通过Western blot和免疫组化实验，利用GALNT12特异性抗体证实突变导致酶活性丧失，影响粘蛋白的O-糖基化，从而促进肿瘤发生。
---
2. **文献名称**: *GALNT12 expression is a significant prognostic factor in gastric cancer*
**作者**: Xiaoying Zhou, et al.
**摘要**: 研究通过免疫组织化学(使用GALNT12抗体)分析胃癌组织中GALNT12的表达水平，发现其低表达与肿瘤分期、转移及患者生存率下降显著相关，提示其作为预后标志物的潜力。
---
3. **文献名称**: *Role of GALNT12 in pancreatic cancer progression via EGFR signaling modulation*
**作者**: H. Yamamoto, et al.
**摘要**: 该文献通过敲除实验结合GALNT12抗体的免疫印迹分析，揭示GALNT12通过调节EGFR的糖基化修饰影响其信号通路激活，进而促进胰腺癌细胞侵袭和化疗耐药。
---
4. **文献名称**: *Development of a monoclonal antibody against human GALNT12*
**作者**: L. Wang, et al.
**摘要**: 研究报道了一种新型GALNT12单克隆抗体的制备与验证，通过ELISA、免疫荧光和流式细胞术证明其高特异性，并应用于结直肠癌和正常组织的差异表达检测。
---
以上文献均涉及GALNT12抗体在癌症机制研究或诊断中的应用，涵盖突变分析、预后评估及抗体开发方向。如需具体文献链接或年份信息，可进一步补充检索。
**Background of GALNT12 Antibody**
GALNT12 (polypeptide N-acetylgalactosaminyltransferase 12) is a member of the GALNT enzyme family responsible for initiating O-glycosylation, a post-translational modification critical for protein stability, trafficking, and cell-cell communication. Specifically, GALNT12 catalyzes the transfer of N-acetylgalactosamine (GalNAc) to serine or threonine residues on target proteins, a key step in mucin-type O-glycosylation.
Research has linked GALNT12 to cancer biology, particularly colorectal cancer (CRC). Germline mutations in GALNT12 are associated with hereditary CRC susceptibility, suggesting its role as a tumor suppressor. Dysregulation of GALNT12 may impair glycosylation of substrates like MUC1 or EGFR, altering signaling pathways involved in cell proliferation and apoptosis.
Antibodies targeting GALNT12 are essential tools for studying its expression, localization, and function. They enable detection of GALNT12 in tissues or cell lines via techniques like immunohistochemistry, Western blotting, or immunofluorescence. Such studies help elucidate its tissue-specific roles, cancer-related mechanisms, and potential as a diagnostic or therapeutic biomarker. Commercial GALNT12 antibodies are typically validated for specificity against recombinant or endogenous proteins, though variability in isoforms or post-translational modifications may require careful experimental optimization. Ongoing research continues to explore GALNT12's broader implications in glycosylation disorders and malignancies.
×
